Fintel reports that on April 8, 2025, Goldman Sachs upgraded their outlook for Eli Lilly and (NYSE:LLY) from Neutral to Buy.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

The drugmaker's stock has dropped by 4.73% in the past ... investors should keep an eye on any recent revisions to analyst forecasts for Eli Lilly. These recent revisions tend to reflect the ...

The stock's performance was ahead of the S ... Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Eli Lilly. These latest adjustments often mirror the ...

Eli Lilly has emerged as a popular growth stock thanks to its strength in the ... Eisai actually revised its full-year 2024 forecast for Leqembi to 42.5 billion yen -- down from the initial ...

On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year. Eli Lilly and Company announced that its board has initiated a stock ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling ...